St. Luke's Hospital, Pennsylvania

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, St. Luke's Hospital, Pennsylvania sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 1 currently recruiting 8 completed later-stage tilt top decile by trial count

St. Luke's Hospital, Pennsylvania: 10 sponsored US clinical trials, 1 recruiting.

St. Luke's Hospital, Pennsylvania sponsors 10 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 8 completed. 5 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hemopneumothorax, with 1 trials.

Top-decile sponsor footprint

St. Luke's Hospital, Pennsylvania ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

10 total, page 1 of 1

RECRUITING NA

Non-Contact Low-Frequency Ultrasound Vs Standard LaLonde Protocol for Fingertip Injury Wound Healing

NCT06813430
ACTIVE NOT RECRUITING Phase 4

The Efficacy of Liposomal Bupivacaine in Ultrasound Guided Supraclavicular Nerve Blocks for Hand and Wrist Surgery

NCT06806410
COMPLETED Phase 4

Exparel Use in Peripheral Nerve Blocks and Local Infiltration for Foot and Ankle Surgery

NCT05494645
COMPLETED Phase 3

Exparel Use in Adductor Canal Block After Total Knee Arthroplasty

NCT04910165
COMPLETED Phase 4

Exparel Use in Bilateral TAP Blocks for Postoperative Pain Control

NCT03878888
COMPLETED

NAPS: Non-awake Versus Awake Placement of Spinal Cord Stimulators

NCT02284542
COMPLETED NA

Visualization in Shoulder Arthroscopy With and Without Epinephrine

NCT01973699
COMPLETED Phase 3

Comparison of Foley Balloon With or Without Traction for the Cervical Ripening

NCT01063244
COMPLETED Phase 2

Role of Antibiotics to Reduce Infectious Complications in Tube Thoracotomy Management of Traumatic Hemopneumothorax

NCT01127880
COMPLETED Phase 2

Effectiveness and Safety Study of Etomidate Versus Midazolam to Help Place a Breathing Tube Outside of the Hospital.

NCT00248729

Phase Distribution

PhaseTrial count
Phase 2 2
Phase 3 2
Phase 4 3

Therapeutic Areas

Hemopneumothorax 1
Wrist Arthropathy 1
Finger Fracture 1
Fracture Fixation 1
Elbow Surgery 1
Wrist Surgery 1
Hand Surgery 1
Dupuytren Contracture 1
Distal Radius Fracture 1
Pneumothorax 1

Where St. Luke's Hospital, Pennsylvania enrollment is open (later-stage tilt)

1 recruiting of 10 indexed (10% open); 8 completed (80%).

Phase mix: 5 late (III/IV) vs 2 early (I/II) (later-stage heavy).

Top condition: Hemopneumothorax (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

St. Luke's Hospital, Pennsylvania: open-pipeline peers nationwide

Peers matched on 10 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

St. Luke's Hospital, Pennsylvania sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 510152025 0%10%20%30%40% Total trials Recruiting share St. Luke's Hospital, PennsylvaniaAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAbiomedAimmune TherapeuticsAltria Client ServicesAlzheimer's Disease Cooperative Study (ADCS)
St. Luke's Hospital, Pennsylvania sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

St. Luke's Hospital, Pennsylvania sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this St. Luke's Hospital, Pennsylvania page

10 registered trials is a research-attention snapshot, not an endorsement of St. Luke's Hospital, Pennsylvania or any single study.

  • 1 of St. Luke's Hospital, Pennsylvania's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Hemopneumothorax is the condition St. Luke's Hospital, Pennsylvania studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hemopneumothorax trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

St. Luke's Hospital, Pennsylvania pipeline card: 10 registered trials from official public datasets.Report a data error.